# Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection

> **NCT00362713** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 12 (actual)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT00362713
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2016-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00362713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00362713, "Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00362713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*